Hydrea Product Description
Hydrea is an oral cytotoxic medicine, providing antimetabolite and antineoplastic effects. Hydrea is used for continuous, intermittent, or concomitant treatment of certain types of neoplastic diseases, including:
- cancer of the cervix
- malignant melanoma
- carcinoma of the neck and head
- chronic and resistant chronic myeloid leukaemia (CML)
- carcinoma of the ovary (including metastatic, inoperable and recurrent)
The maximum single dose of Hydrea is 80 mg. Hydrea tablets can be administered for cancer monotherapy or in combination with other cytotoxic agents and/or together with radiotherapy (RTx).
If you’ve missed a dose of Hydrea, use it as soon as you think about it, but only in case it is not the time for your next prescribed dose. Do not use two doses of this antineoplastic agent on the same day. If you happened to remember about the missed Hydrea dose on the next day, skip the missed dose.
The patients with neoplastic diseases in the head, neck or cervix are prescribed with Hydrea for potentiation of the antineoplastic effects of RTx. The application of Hydrea pills should be started at least 1 week before RTx, and continued after RTx, if necessary.
Hydrea capsules are recommended to be stored at room temperature not above 25°C, however, a short-term storage is permitted up to 30°C. Keep this antineoplastic agent in an original container to protect the capsules from excessive moisture and heat.
Hydrea Safety Information
Pregnant women should take extra caution, while using Hydrea, as this drug may inflict damage to the fetal health. Also, this antineoplastic drug is not recommended for the patients with venereal diseases, disorders of liver, nervous system or pancreas.
The information about chronic myeloid leukaemia and cancer of the cervix, contained in review of Hydrea, is intended for informational purposes only, so it is not meant to substitute for the consultation, treatment or advice of the health care specialist. In no event, the online pharmacy is responsible for any kind of damage or injury, arising from the incorrect use of the information about antineoplastic agent Hydrea.
Hydrea Side Effects
If Hydrea is used in combination with a radiation therapy, certain myelotoxic effects (thrombocytopenia, leukopenia, macrocytosis, anaemia), or gastrointestinal distress (diarrhoea, vomiting, stomatitis, constipation, nausea) can be observed. High doses of Hydrea may cause drowsiness.
Less common undesirable effects of Hydrea include skin ulceration, hyperpigmentation, bleeding, dizziness, anorexia, fever, rash, hallucinations, alopecia, headache, melanonychia, asthenia, convulsions or disorientation. Usually, Hydrea undesirable effects disappear within two weeks after the discontinuation of the oral antineoplastic therapy.